Cost-Efficacy Analysis of the MONET Trial Using UK Antiretroviral Drug Prices

Brian Gazzard, Andrew Hill and Anne Anceau
Additional contact information
Brian Gazzard: Chelsea and Westminster Hospital, London, UK
Andrew Hill: Pharmacology Research Laboratories, University of Liverpool, Liverpool, UK
Anne Anceau: Janssen-Cilag, Issy-les-Moulineaux, France

Applied Health Economics and Health Policy, 2011, vol. 9, issue 4, pages 217-223

Abstract: Background: In virologically suppressed patients, switching to darunavir/ritonavir (DRV/r) monotherapy maintains HIV RNA suppression, and could also lower treatment costs. Objective: The purpose of this analysis was to calculate the potential cost savings from the use of DRV/r monotherapy in the UK. Methods: In the MONET trial, 256 patients with HIV RNA <50 copies/mL on current highly active antiretroviral therapy (HAART) for over 24 weeks (non-nucleoside reverse-transcriptase inhibitor [NNRTI] based [43%] or protease inhibitor [PI] based [57%]), switched to DRV/r 800/100 mg once daily, either as monotherapy (n - 127) or with two NRTIs (n - 129). The UK costs per patient with HIV RNA <50 copies/mL at week 48 (responders) were calculated using a 'switch included' analysis to account for additional antiretrovirals taken after initial treatment failure. By this analysis, efficacy was 93.5% versus 95.1% in the DRV/r monotherapy and triple therapy arms, respectively. British National Formulary 2009 values were used. Results: Before the trial, the mean annual cost of antiretrovirals was £6906 for patients receiving NNRTI-based HAART, and £8348 for patients receiving PI-based HAART. During the MONET trial, the mean annual per-patient cost of antiretrovirals was £8642 in the triple therapy arm, of which 55% was from NRTIs and 45% from PIs. The mean per-patient cost in the monotherapy arm was £4126, a saving of 52% versus triple therapy. The mean cost per responder was £9085 in the triple therapy arm versus £4413 in the DRV/r monotherapy arm. Conclusions: Based on the MONET results, the lower cost of DRV/r monotherapy versus triple therapy in the UK would allow more patients to be treated for fixed budgets, while maintaining HIV RNA suppression at <50 copies/mL. If all patients meeting the inclusion criteria of the MONET trial in the UK were switched to DRV/r monotherapy, there is the potential to save up to £60 million in antiretroviral drug costs from the UK NHS budget.

Keywords: Budget-impact-analysis; Cost-effectiveness; Darunavir/ritonavir; HIV-infection. (search for similar items in EconPapers)
JEL-codes: C D I Z I1 I19 I18 I11 (search for similar items in EconPapers)
Date: 2011
References: Add references at CitEc
Citations Track citations by RSS feed

Downloads: (external link)
http://healtheconomics.adisonline.com/pt/re/ahe/pd ... -201109040-00002.pdf (application/pdf)
http://healtheconomics.adisonline.com/pt/re/ahe/fu ... -201109040-00002.htm (text/html)
Pay per view

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: http://EconPapers.repec.org/RePEc:wkh:aheahp:v:9:y:2011:i:4:p:217-223

Access Statistics for this article

Applied Health Economics and Health Policy is edited by Tim Wrightson

More articles in Applied Health Economics and Health Policy from Springer Healthcare | Adis
Series data maintained by Dave Dustin ().